Media stories about Sierra Oncology (NASDAQ:DNAI) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research group ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Sierra Oncology earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.6071134531253 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

WARNING: This report was first published by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was illegally stolen and reposted in violation of United States & international copyright & trademark laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/08/06/sierra-oncology-dnai-receiving-somewhat-favorable-press-coverage-report-finds.html.

Sierra Oncology Company Profile

Sierra Oncology, Inc, formerly ProNAi Therapeutics, Inc, is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network.

Insider Buying and Selling by Quarter for Sierra Oncology (NASDAQ:DNAI)

Receive News & Ratings for Sierra Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sierra Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.